Tirabrutinib

Tirabrutinib

Tirabrutinib

Chemical compound

Tirabrutinib (brand name Velexbru) is a drug used for the treatment of autoimmune disorders and hematological malignancies.[1][2]

Quick Facts Clinical data, Trade names ...

Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma.[1] In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences[3] in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis.[1]

Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase.[4]

References

  1. [1]
    Dhillon S (June 2020). "Tirabrutinib: First Approval". Drugs. 80 (8): 835–840. doi:10.1007/s40265-020-01318-8. PMID 32382949. S2CID 218531327.
  2. [2]
    "Tirabrutinib". NCI Drug Dictionary. National Institutes of Health.
  3. [3]
    "Tirabrutinib - Gilead Sciences/Ono Pharmaceutical". Adis Insight.
  4. [4]
    Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, et al. (April 2020). "Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition". Biochimica et Biophysica Acta (BBA) - General Subjects. 1864 (4): 129531. doi:10.1016/j.bbagen.2020.129531. PMID 31953125.
Share this article:

This article uses material from the Wikipedia article Tirabrutinib, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.